Literature DB >> 24357731

B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia.

Yongwei Zheng1, Alexander W Wang, Mei Yu, Anand Padmanabhan, Benjamin E Tourdot, Debra K Newman, Gilbert C White, Richard H Aster, Renren Wen, Demin Wang.   

Abstract

Immune complexes consisting of heparin, platelet factor 4 (PF4), and PF4/heparin-reactive antibodies are central to the pathogenesis of heparin-induced thrombocytopenia (HIT). It is as yet unclear what triggers the initial induction of pathogenic antibodies. We identified B cells in peripheral blood of healthy adults that produce PF4/heparin-specific antibodies following in vitro stimulation with proinflammatory molecules containing deoxycytosine-deoxyguanosine (CpG). Similarly, B cells from unmanipulated wild-type mice produced PF4/heparin-specific antibodies following in vitro or in vivo CpG stimulation. Thus, both healthy humans and mice possess preexisting inactive/tolerant PF4/heparin-specific B cells. The findings suggest that breakdown of tolerance leads to PF4/heparin-specific B-cell activation and antibody production in patients developing HIT. Consistent with this concept, mice lacking protein kinase Cδ (PKCδ) that are prone to breakdown of B-cell tolerance produced anti-PF4/heparin antibodies spontaneously. Therefore, breakdown of tolerance can lead to PF4/heparin-specific antibody production, and B-cell tolerance may play an important role in HIT pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24357731      PMCID: PMC3916881          DOI: 10.1182/blood-2013-11-540781

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis.

Authors:  G P Visentin; M Moghaddam; S E Beery; J G McFarland; R H Aster
Journal:  J Lab Clin Med       Date:  2001-07

2.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

3.  Characterization of the humoral immune response in heparin-induced thrombocytopenia.

Authors:  J S Suh; M I Malik; R H Aster; G P Visentin
Journal:  Am J Hematol       Date:  1997-03       Impact factor: 10.047

4.  Impact of the patient population on the risk for heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J A Sheppard; P Horsewood; P J Simpson; J C Moore; J G Kelton
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

5.  Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.

Authors:  Elizabeth A Leadbetter; Ian R Rifkin; Andreas M Hohlbaum; Britte C Beaudette; Mark J Shlomchik; Ann Marshak-Rothstein
Journal:  Nature       Date:  2002-04-11       Impact factor: 49.962

6.  Protein kinase Cdelta controls self-antigen-induced B-cell tolerance.

Authors:  Ingrid Mecklenbräuker; Kaoru Saijo; Nai-Ying Zheng; Michael Leitges; Alexander Tarakhovsky
Journal:  Nature       Date:  2002-04-25       Impact factor: 49.962

7.  Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta.

Authors:  Akimoto Miyamoto; Keiko Nakayama; Hiroyuki Imaki; Sachiko Hirose; Yi Jiang; Masaaki Abe; Tadasuke Tsukiyama; Hiroyasu Nagahama; Shigeo Ohno; Shigetsugu Hatakeyama; Keiichi I Nakayama
Journal:  Nature       Date:  2002-04-25       Impact factor: 49.962

8.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

9.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more
  17 in total

1.  Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.

Authors:  M Joglekar; S Khandelwal; D B Cines; M Poncz; L Rauova; G M Arepally
Journal:  J Thromb Haemost       Date:  2015-07-14       Impact factor: 5.824

Review 2.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

3.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

Review 4.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 5.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

6.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

Review 7.  Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II.

Authors:  Elisavet Grouzi
Journal:  J Blood Med       Date:  2014-08-13

8.  Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

Authors:  B Singh; A Kanack; A Bayas; G George; M Y Abou-Ismail; M Kohlhagen; M Christ; M Naumann; K Moser; K Smock; A Grazioli; D Murray; A Padmanabhan
Journal:  medRxiv       Date:  2021-09-24

9.  Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Authors:  Sanjay Khandelwal; Joann Ravi; Lubica Rauova; Alexandra Johnson; Grace M Lee; Jennifer B Gilner; Sreenivasulu Gunti; Abner L Notkins; Maragatha Kuchibhatla; Michael Frank; Mortimer Poncz; Douglas B Cines; Gowthami M Arepally
Journal:  Blood       Date:  2018-10-11       Impact factor: 25.476

10.  Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin.

Authors:  Satish Maharaj; Simone Chang; Karan Seegobin; James Morales; Agnes Aysola; Fauzia Rana; Marwan Shaikh
Journal:  Exp Hematol Oncol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.